Literature DB >> 6133544

Benzodiazepines impair smooth pursuit eye movements.

P R Bittencourt, P Wade, A T Smith, A Richens.   

Abstract

Five healthy male volunteers received single oral doses of 10 mg diazepam, 20 mg temazepam and placebo, in a double-blind, randomised fashion. Smooth pursuit eye movement velocity and serum benzodiazepine concentration were measured before and after at 0.5,1,1.5,2,3,4,6,9 and 12 h after administration of the treatments. Significant decrease in smooth pursuit eye movement velocity as compared to placebo was observed between 0.5-2 h after temazepam, and between 1-2 h after diazepam. Smooth pursuit eye movement velocity was log-linearly correlated with serum temazepam and diazepam concentration. The results demonstrate the relationship between serum benzodiazepine concentration and its effect on an objective measure of oculomotor performance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133544      PMCID: PMC1427870          DOI: 10.1111/j.1365-2125.1983.tb01495.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Smooth-pursuit eye movements, and diazepam, CPZ, and secobarbital.

Authors:  P S Holzman; D L Levy; E H Uhlenhuth; L R Proctor; D X Freedman
Journal:  Psychopharmacologia       Date:  1975-10-31

2.  Blood levels and electroencephalographic effects of diazepam and bromazepam.

Authors:  M Fink; R E Weinfeld; M A Schwartz; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

3.  Determination of 1,4-benzodiazepines and -diazepin-2-ones in blood by electron-capture gas-liquid chromatography.

Authors:  J A de Silva; I Bekersky; C V Puglisi; M A Brooks; R E Weinfeld
Journal:  Anal Chem       Date:  1976-01       Impact factor: 6.986

4.  Cross-national study of the extent of anti-anxiety-sedative drug use.

Authors:  M B Balter; J Levine; D I Manheimer
Journal:  N Engl J Med       Date:  1974-04-04       Impact factor: 91.245

5.  The action of sedatives on brain stem oculomotor systems in man.

Authors:  H Norris
Journal:  Neuropharmacology       Date:  1971-03       Impact factor: 5.250

6.  The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration.

Authors:  P R Bittencourt; P Wade; A T Smith; A Richens
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

Review 7.  Benzodiazepines in the treatment of epilepsy. A review.

Authors:  T R Browne; J K Penry
Journal:  Epilepsia       Date:  1973-09       Impact factor: 5.864

8.  [The effect of diazepam (Valium) on the saccadic eye movements in man].

Authors:  J C Aschoff
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1968

9.  Eye-tracking and optokinetic nystagmus. Results of quantitative testing in patients with well-defined nervous system lesions.

Authors:  R W Baloh; V Honrubia; A Sills
Journal:  Ann Otol Rhinol Laryngol       Date:  1977 Jan-Feb       Impact factor: 1.547

10.  Eye-tracking patterns in schizophrenia.

Authors:  P S Holzman; L R Proctor; D W Hughes
Journal:  Science       Date:  1973-07-13       Impact factor: 47.728

View more
  21 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.

Authors:  Remco W M Zoethout; Rik C Schoemaker; Lineke Zuurman; Hans van Pelt; Albert Dahan; Adam F Cohen; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

3.  Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Authors:  Anne C Baakman; Rob Zuiker; Joop M A van Gerven; Nicholas Gross; Ronghua Yang; Michael Fetell; Ari Gershon; Yossi Gilgun-Sherki; Edward Hellriegel; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2019-03-14       Impact factor: 4.335

Review 4.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

5.  An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Authors:  Anne Catrien Baakman; Ricardo Alvarez-Jimenez; Robert Rissmann; Erica S Klaassen; Jasper Stevens; Sebastiaan C Goulooze; Jeroen C G den Burger; Eleonora L Swart; Joop M A van Gerven; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2017-04-08       Impact factor: 4.335

6.  The influence of antihistamines on human performance.

Authors:  A W Gaillard; A Gruisen; R de Jong
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Effects of diazepam on closed- and open-loop optokinetic nystagmus (OKN) in humans.

Authors:  Jing Tian; Min Wei; Pei-Ji Liang; Fuchuan Sun
Journal:  Exp Brain Res       Date:  2003-09-02       Impact factor: 1.972

Review 8.  Biomarkers for the effects of benzodiazepines in healthy volunteers.

Authors:  S J de Visser; J P van der Post; P P de Waal; F Cornet; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

9.  Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

Authors:  Erik T te Beek; Justin L Hay; Jonathan N Bullman; Clare Burgess; Kimberly J Nahon; Erica S Klaassen; Frank A Gray; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

10.  The effects of acrivastine (BW825C), diphenhydramine and terfenadine in combination with alcohol on human CNS performance.

Authors:  A F Cohen; M J Hamilton; A W Peck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.